Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

Journal for immunotherapy of cancer·2026
Same author

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50.

Cancer cell international·2026
Same author

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

NPJ precision oncology·2026
Same author

FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same journal

Research advances and application prospects of CAR-T therapy in the treatment of age-related diseases.

Frontiers in immunology·2026
Same journal

Machine learning-driven identification and immunohistochemical validation of an integrated immune-inflammatory phenotype for disease-free survival stratification in breast cancer.

Frontiers in immunology·2026
Same journal

Modified treatment protocol for pediatric systemic lupus erythematosus-associated hemophagocytic lymphohistiocytosis with central nervous system involvement: a case report.

Frontiers in immunology·2026
Same journal

Exploratory characterization of IgG1/IgG4 glycosylation and monocyte-derived dendritic cell responses in esophageal squamous cell carcinoma.

Frontiers in immunology·2026
Same journal

JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases.

Frontiers in immunology·2026
Same journal

Cross-talk among novel programmed cell death pathways: a decisive network in renal ischemia-reperfusion injury.

Frontiers in immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 3, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.2K

Lymphoma Immunotherapy: Current Status.

Roberta Zappasodi1, Filippo de Braud2, Massimo Di Nicola3

  • 1Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center , New York, NY , USA.

Frontiers in Immunology
|September 22, 2015
PubMed
Summary
This summary is machine-generated.

Immunotherapy for lymphomas leverages immune responsiveness. New strategies aim to overcome resistance in B-cell non-Hodgkin lymphomas (B-NHL) by combining novel agents to induce anti-lymphoma immunity.

Keywords:
B-cell lymphomaadaptive immune responseanticancer vaccinesdendritic cellsimmunotherapytumor-associated antigens

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.7K

Related Experiment Videos

Last Updated: Apr 3, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.2K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.7K

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Lymphomas exhibit immune responsiveness, with B-cell non-Hodgkin lymphomas (B-NHL) interacting with the immune microenvironment.
  • Spontaneous regressions suggest the potential for therapeutic antitumor immunity in B-NHL patients.
  • Current immunotherapies, like rituximab targeting CD20, are effective but insufficient for curing all B-NHL patients due to relapse and resistance.

Purpose of the Study:

  • To review the rationale and development of immunotherapies for lymphomas, focusing on B-cell non-Hodgkin lymphomas.
  • To discuss novel immunotherapeutic approaches and their potential in combination therapies.
  • To explore strategies for overcoming resistance and improving cure rates in B-NHL.

Main Methods:

  • Review of existing literature on lymphoma immunology and immunotherapy.
  • Analysis of clinical effectiveness and limitations of current treatments, including rituximab.
  • Exploration of emerging immunotherapeutic strategies such as tumor-specific antigen vaccines, engineered T cells, and immune checkpoint inhibitors.

Main Results:

  • Rituximab targeting CD20 is a clinically effective strategy but does not cure all B-NHL patients.
  • Tumor-specific antigen vaccines have shown initial promise but require further clinical benefit demonstration.
  • Novel agents like engineered T cells, co-stimulatory agonists, and checkpoint inhibitors offer new avenues for immune stimulation.

Conclusions:

  • Combining multiple novel immunotherapeutic agents holds promise for breaking barriers to anti-lymphoma immunity.
  • Future strategies may involve synergistic combinations to enhance immune effector functions and counteract immunosuppression in B-NHL.
  • Further research and clinical trials are needed to optimize combination immunotherapies for improved B-NHL treatment outcomes.